,I, Introduction A. Characteristics of Se Selenium is a member of the oxygen group of elements; it is primarily anionic but may form cations in non-aqueous solvents. Its normal oxidation states are selenate, the 6 + form (Se (VI); selenite, the 4 + (Se (IV); the very transient 2 + form, and the selenide 2 form, to which it is easily reduced. Pulse radiolysis studies (e.g., Kl&ning and Sehested, 1986) reveal the presence of Se (V) forms in aqueous selenate/selenites, reflecting the rapid reduction or oxidation of the two higher forms. The structures of Se clusters have been investigated by Hohl, et aL, (1987) .
Selenium is an essential micronutrient; its biochemical functions have been reviewed briefly by Wendel (1992) , and by Burk (1991) and Nve (1991) amongst others. It reduces the toxicities of Hg, Pb, Cd, Cu, Ni, and As (Cuvinaralar and Furness, 1991; Parizek, 1990; Paulsson and Lundbergh, 1991; Taketani, et aL, 1991; Ingersoll, et HSgberg and Alexander, 1986) and the nephrotoxicity of cisplatin (Baldew, et al., 1991) . By contrast, Se deficiency enhances the nephrotoxicity of cephaloridine, a betalactam antibiotic (Kays, et aL, 1991) . It is strongly nucleophilic in biological systems and usually more reactive in biological molecules than its sulfur analogues (see, for example, Nosz&l, et aL, 1991) . In this reaction (Table 1) with n-butylamine the selenocysteamine shows higher reaction rates by two orders of magnitude (Mautner, 1956 ); the same relationship holds for Se nucleophilicity over sulfur in chloroethyl sulfides and selenides (Kang and Spears, 1990) . The selenocysteinyl sites of glutathione peroxidase (GSHPx) demonstrate similarly greater formation constants with methyl Volume 1, Nos. [2] [3] 1994 Selenium ,Species: Uptake, Transformation and Toxicities in Differing
Substrates and their Pharmaceutical Applications mercury than the corresponding thiol complexes which were thought to detoxify this form of Hg (Arnold et aL, 1986) . Selenium radicals also react with amino acids by several orders of magnitude more rapidly than halide or pseudo-halide radicals (Badiello, 1992) .
B. AllrOaches in research
For the last forty years, interest in selenium as a drug component has fluctuated, depending on several factors including the degree to which its chemistry was understood to differ from that of sulphur, the recognition of its physiological roles, investigations into its mutagenic capacities, and the degree to which scientists in one discipline were aware of advances made in other fields. Studies conducted on how organisms in seleniferous environments detoxified Se (Abu-Erreish, et aL, 1968; Fleming and Alexander, 1975; Chau, et al., 1976; ) Underwood, 1981; Tappel, 1980; Ganther, 1980) ; theory-based studies compare the known properties of S compounds with the activities of Se-substituted molecules, such as the substitution of selenium for chloride in 6-chloropurine ribosides (Mautner, 1956; Mautner, et aL, 1963; Scovill, 1992) or the synthesis of 2-chloro-ethylselenides (Khalil and Maslat, 1991) . The use of Se as a ligand has been exploited more by synthetic inorganic chemists (e.g., Hoots, et aL, 1984) than by others in the field but its liganding characteristics are useful in the synthesis of biologically-active molecules.
C. Se metaboli,m
Se normally enters the body in its more oxidised forms, as selenate or selenite, is reduced to selenide, and is absorbed and/or excreted, depending on Se status, energy demands, dietary factors (e.g., lipid intake) and the toxic or heavy-metal burden carried by the organism. Selenite and selenious acid are toxic; its most oxidised state, selenate, is non-toxic. In normal metabolism, selenate reduction occurs via GSH to selenite which is then more quickly reduced by GSH reductase and/or methylation, as shown by the following equations (Table 2) , summarised in Whiting, et aL, (1980) . Selenate reduction by GSH and other sulfhydryl compounds is shown in Eqo 1; selenite reduction (Eq. 2) and further reactions take place in seconds. Reduction of selenite proceeds via the selenotrisulfide (GS-Se-SG) which is relatively stable, and via the persulfide, (GS-Se) which is highly reactive. Selenide is protected against oxidation (Eq. 8) by the presence of excess sulfhydryls (Eq. 9).
Protein incorporation may follow, or the product may be excreted after the formation of di-or trimethylselenides. The formation of methylated products, and the route of excretion, depends on the organism, on the form of selenium in the exposure, on the amount of selenium in the dose, on the selenium status of the organism, and on the presence of interactive factors, such as the sex of the animal, its hormone status (especially pregnancy or lactation in females), and the heavy-metal body load (e.g., Janghorbani, et aL, 1991; Parizek, 1990) . That these interactive factors have a bearing on the use of Se in pharmaceuticals may be obvious; it is also significant that the selenobetaine synthetics, in bypassing the hydrogen selenide pool, may bypass at least some of these metabolic interactions which can potentiate Se or interaction factor toxicities.
II. Se in bioloaical materials
A, Selenocysteine Selenium may be most familiar through knowledge of the consequences of nutritional deficits, or through its role as the catalytic moiety of glutathione peroxidase. These concepts are related in that Se deficiency lowers GSHPx levels and activity with severe consequences for the organism. Briefly put, Se in GSHPx appears as a selenocysteine molecule, probably located at the N-terminal ends of alpha helices in what Epp, et a/., (1983) Bock, et al., (1991) proposed that the evidence presented by them and by the Stadtman group at the National Institutes of Health (e.g., Stadtman, 1990; Politino, et al., 1991) (Pumford, et al, 1992) has been found to be 97% homologous with a non-selenocysteine selenium-binding protein of 56 kDa (Kang and Spears, 1990 Norppa, et aL, (1980a-c) , as they observed. Their tests were negative in bone marrow or primary spermatocytes of mice after i.p. injection of 0.8 mg/kg bd.wt.; on CH bone marrow, 0.3-6.0 mg/kg bd.wt, injections of sodium selenite induced SCE and aberrations at the 3-6 mg/kg dose range. Sirianni and Huang (1983) , testing 0-64 I.tg/ml of NaSeO32-, NaSeO42-and HSe2-with and without $9, found the lower oxidation states induced more SCE than selenate in the CH V79 cell line. Ray (1984) , measuring SCE induced by doses of [7.95 x 10-6] M NaSeO32-, found that reduced glutathione was required for conversion of selenite to its SCE-inducing form, suggesting that this conversion runs on the same pathway as normal RBC metabolism of sodium selenite. Anjaria and Madhvanath (1988) noted that the presence of glutathione enhanced the selenite-induced genotoxicity in the yeast BZ34. The rate of genetic damage rose and then fell over the period of their five-hour experiments.
Kramer and Ames (1988) , Hung, et al., (1988) and Garberg, et al., (1988) have demonstrated that selenite genotoxicity is a function of oxidative damage. Kramer and Ames ascribe this to the reaction of intracellular thiols and selenite, producing peroxide and superoxide radicals; Garberg minor corrigendum appeared in Mutation Res. (1991) 242,7: 293. and co-workers found that DNA fragmentation was inhibited by cyanide and mercuric chloride. Hung and co-workers found a significant protective effect against oxidative single-strand breaks (SSB) at the lower concentrations of 10-5-10-7 M NaSeO32-, but a significant damaging effect at 10-4 M NaSeO32- Balansky (1991) By using the development of S-analogues of naturally-occurring purine and pyramidine bases e.g., 6-mercaptopurine, 6-methylmercaptopurine and 2-thiouracil-as paradigms, Mautner synthesised a number of compounds between 1956 and 1962: 6-Se-purine, 6-Me-Se-purine, 2-selenouracil, 2,4-diselenouracil, 2-selenothymine (Mautner, 1956) ; and later, selenoguanine, diselenothymine, and 5-methylcytosine (Mautner, et al., 1963) . 6-Se-purine was prepared by the addition of sodium hydrogen selenide to 6-chloropurine; a similar reaction adding selenourea produced a 92% yield. The selenouracils were synthesised using selenourea instead of thiourea in the thenstandard uracil synthetic methods.
Hypoxanthine (oxypurine), mercaptopurine and the 6-selenpurine were methylated, producing hypsochromic shifts in UV absorption with increasing atomic number, and an increase in acidity of the compounds. The polarisability of the carbonyl, thiocarbonyl and selenocarbonyl bonds increases in passing up the periodic table.
Of these compounds, the selenopurine, tested on the growth of mouse lymphoma L-1210 cells, demonstrated a level of activity equivalent to that of 6-mercaptopurine, then in use as a clinical anti-leukaemic agent. In other mouse tumour studies the thiopurine was more active. On the other hand, the selenopurine was more anti-bacterial and had a greater ability to inhibit formate incorporation into purines than the sulphur analogue. 6-selenopurine was also found to have Cu-chelating properties equal to those of 8-hydroxyquinoline and exceeding those of hypoxanthine. In an effort to improve the performance and stability of the selenopurine, Mautner's group (Mautner, et al., 1963) made selenoguanine as an analogue of 6-thioguanine and compared this activity against implanted L5178Y lymphoma in mice, in 6C3HED lymphosarcoma cell lines, and in mice bearing an ascites cell form of sarcoma 180. In the latter case the selenoguanine produced tumour inhibition over a wider dose range; in the former whilst both thioguanine and selenoguanine were inhibitory, selenoguanine was the least toxic of the two. Selenocytosine was compared with thiocytosine as an anti-tumour agent, but neither compound significantly prolonged the survival time of mice implanted with the L5178Y lymphoma.
Mautner also studied the effects of Se-substitution on the lipophilicity of phenobarbital, a 2-selenobarbiturate (Mautner and Clayton, 1959) , and compared the transacylation rates of thioacyl and selenoacyl analogs in reaction with n-butylamine (Mautner and G0nther, 1961) . Se substitution of O in phenobarbital increased the drug's lipophilicityoFrom this structure, GQnther, et al., (1992) those of deficiency manifested in cardiac myopathy and so-called 'white muscle disease'-and of excess, manifested in 'blind staggers'-neurological and skeletal muscle impairment-and sloughing of hooves and other keratinised tissues. The principal concern was the detoxifying of Se through methylation Nahapetian, et al., 1983; McConnell and Portman, 1952; Obermeyer, et ai., 1971; Foster, et al., 1986) ; the production of hydrogen selenide was considered to be the intoxifying step in Se toxicity. The forms of Se most productive of MeSe were investigated for many years; in the course of these it was noted (Foster, et. al., 1986b ) that trimethylselenium could not be formed from selenobetaine by decarboxylation.
Methyl compounds were long held to be biologically inactive. However, two further types of discoveries have led to the present state of selenobetaine cytotoxins. First, methylated species can be remobilised by demethylation, in soils (Oremland, et aL, 1990) ; in vivo, trimethylselenonium ion, via betaine:homocysteine methyltransferase, can be demethylated to form dimethyl selenide and methione (Goeger and Ganther 1993) . Secondly, whilst in theory methylated species should be active through their increased lipophilicity, no evidence of this was found until 1989, when Ganther's group reported an observation that methyI-Se was found in mouse kidney, where they didn't expect it (Stadtman, 1990) . They also reported a synergistic toxicity between arsenite and methyl-Se compounds (Kraus and Ganther, 1989) . In normal tissue seven organo-Se compounds were shown to be toxic when administered with arsenite (Table 3) and this toxicity held true for tumour suppression in dimethylbenz(a)anthracene induced mammary tumours in rats (Ip and Ganther, 1990) . In a later study (Ip and Ganther, 1992) , the arsenite addition was dropped, and paired S/Se compounds were tested for DMBA-induced tumour suppression (cysteamine/selenocystamine; sulfobetaine/selenobetaine; S-methylcysteine; Se-methylselenocysteine). In the sulfur series, only cysteamine and S-methylcysteamine produced anticancer activity, and the levels required for these responses were 500-750 times as high as those of the corresponding Se analogues.
IV, Conclusions
The mechanisms of Se genotoxicity both for normal and tumour cells are not settled, but it is established that an inverse relationship exists between Se content of soils and water and the incidence of human tumours. Ganther's group (Wilson, et aL, 1992) take the view that DNA fragmentation resulting from selenite exposure occurs during reductive metabolism and not from an accumulation of the methylated by-product. The methylated compounds alter the long-term proliferative potential of cells via mechanisms distinct from those associated with cell injury and death by necrosis. Se supplementation can inhibit tumorigenesis in rats, depending on the dose of the carcinogen and dietary fat intake (Ip, 1981) . Banner and others (1981) found that pretreatment with sodium selenite did not reverse or inhibit the acute inhibition of RNA and DNA synthesis induced by methyl-azoxymethanol (MAM); they conclude that Se exerts its protective effect by some mechanism other than interference with carcinogen activation by microsomes. Balansky (1991 Balansky ( , 1992 has published two papers which he feels show conclusively that both Se genotoxicity and its antitumour effects are a function of timing of dose and the presence or absence of possible comutagens. It is clear that the exploitation of the reactivity of selenium must be mediated by the properties of its carrier molecules, and by a better understanding of its metabolic chemistry. This is impossible without better communication between structural/analytical chemists and biological chemists of their respective investigations and their results.
